Under ipilimumab treatment, homozygous patients for the 158-valine (158V) alloform of FcγRIIIA (FcγRIIIA-158VV), whose tumor has a high neoantigenic burden, have a better survival rate than any other patients. The gene discussed is FCGR3A; the disease is neoplasm.